Clinical Trial: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

U.S., Feb. 26 -- ClinicalTrials.gov registry received information related to the study (NCT06276361) titled 'Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia' on Feb. 16.

Brief Summary: This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths in participants with schizophrenia.

Study Type: Interventional

Condition: Schizophrenia

Intervention: * Drug: Oral risperidone; QUAR F1/2, Dose 1 - Gluteal

Dose level 1

* Drug: Oral risperidone; QUAR F1/2, Dose 2 - Gluteal

Dose...